Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 01 2020 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, announced today that it has received
notification from Nasdaq that it has regained compliance with the
minimum bid price for continued listing on the Nasdaq Capital
Market, as the closing bid price of Outlook Therapeutics’ common
stock has been at $1.00 or greater for 10 consecutive trading days.
Accordingly, this matter is now closed.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop ONS-5010/LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab-vikg for use in retinal indications, including wet
AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics
expects to commercialize it as the first and only FDA-approved
ophthalmic formulation of bevacizumab-vikg for use in treating a
range of retinal diseases in the United States, United Kingdom,
Europe, Japan, China and other markets. Outlook Therapeutics
expects to file ONS-5010 with the U.S. FDA as a new BLA under the
PHSA 351(a) regulatory pathway, initially for wet AMD. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries: Harriet Ullman Assistant
Vice President LaVoieHealthScience T:
617-669-3082 hullman@lavoiehealthscience.com
Investor Inquiries: Jenene Thomas Chief
Executive Officer JTC Team, LLC T:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024